Advertisement

Long-term Follow-up of a Matched Cohort Study Evaluating the Role of Adjuvant Radiotherapy for Organ-confined Prostate Cancer With a Positive Surgical Margin

      Objective

      To evaluate if adjuvant radiation therapy (ART) is associated with improved long-term oncologic outcomes for pT2N0R1 prostate cancer (PCa).

      Methods

      Men with pT2N0 PCa and a single positive surgical margin following radical prostatectomy and pelvic lymphadenectomy were identified (1987-1996). Men who received ART were matched 1:1 to men who did not receive ART based on age, year of surgery, Gleason score, preoperative prostate-specific antigen, site of positive surgical margin, and DNA ploidy. Biochemical recurrence (BCR), local recurrence, distant metastasis, and overall survival (OS) were compared between groups in time-to-event analyses.

      Results

      The cohort included 152 men (76 per group) with a median follow-up of 20 years (interquartile range 19,22). ART was associated with a lower cumulative incidence of BCR (25% vs 52%; P <.001) and local recurrence (3% vs 12%; P = .03), but no significant differences in cumulative incidence of distant metastasis (10% vs 7%; P = .44) or in probability of OS (56% vs 68%; P = .08) at 20 years. In competing risks models, receipt of ART was associated with reduced risks of BCR (hazard ratio [HR] = 0.40; 95% confidence interval [CI] 0.23-0.70; P <.001) and local recurrence (HR = 0.21; 95% CI .05-0.98; P = .05), but not distant metastasis (HR = 1.56; 95% CI 0.51-4.75; P = .43). In the Cox model, ART was not associated with improved OS (HR = 1.56; 95% CI 0.94-2.57; P = .08).

      Conclusion

      ART was associated with reduced risks of BCR and local recurrence for men with pT2N0R1 PCa. However, ART was not significantly associated with metastasis-free or OS benefits, as recurrences in these patients generally followed an indolent trajectory with 20 years of median follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yossepowitch O.
        • Briganti A.
        • Eastham J.A.
        • et al.
        Positive surgical margins after radical prostatectomy: a systematic review and contemporary update.
        Eur Urol. 2014; 65: 303-313
        • Thompson I.M.
        • Valicenti R.K.
        • Albertsen P.
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
        J Urol. 2013; 190: 441-449
        • Hoffman K.E.
        • Nguyen P.L.
        • Chen M.H.
        • et al.
        Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
        J Urol. 2011; 185: 116-120
        • Sineshaw H.M.
        • Gray P.J.
        • Efstathiou J.A.
        • Jemal A.
        Declining use of radiotherapy for adverse features after radical prostatectomy: results from the national cancer data base.
        Eur Urol. 2015; 68: 768-774
        • Kalbasi A.
        • Swisher-McClure S.
        • Mitra N.
        • et al.
        Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high-risk pathologic features.
        Cancer. 2014; 120: 3089-3096
        • Thompson Jr, I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
        JAMA. 2006; 296: 2329-2335
        • Thompson I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial.
        J Urol. 2009; 181: 956-962
        • Bolla M.
        • van Poppel H.
        • Collette L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578
        • Bolla M.
        • van Poppel H.
        • Tombal B.
        • et al.
        Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).
        Lancet. 2012; 380: 2018-2027
        • Wiegel T.
        • Bottke D.
        • Steiner U.
        • et al.
        Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
        J Clin Oncol. 2009; 27: 2924-2930
        • Wiegel T.
        • Bartkowiak D.
        • Bottke D.
        • et al.
        Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.
        Eur Urol. 2014; 66: 243-250
        • Efstathiou J.A.
        Postoperative radiation for prostate cancer.
        Lancet. 2012; 380: 1974-1976
        • D'Amico A.V.
        Adjuvant versus salvage post-prostatectomy radiation therapy: a critical review of the evidence.
        J Urol. 2013; 190: 450-451
        • Leibovich B.C.
        • Engen D.E.
        • Patterson D.E.
        • et al.
        Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin.
        J Urol. 2000; 163: 1178-1182
        • Pound C.R.
        • Partin A.W.
        • Eisenberger M.A.
        • Chan D.W.
        • Pearson J.D.
        • Walsh P.C.
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Pacholke H.D.
        • Wajsman Z.
        • Algood C.B.
        • Morris C.G.
        • Zlotecki R.A.
        Postoperative adjuvant and salvage radiotherapy for prostate cancer: impact on freedom from biochemical relapse and survival.
        Urology. 2004; 64: 982-986
        • Trabulsi E.J.
        • Valicenti R.K.
        • Hanlon A.L.
        • et al.
        A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.
        Urology. 2008; 72 (discussion 1302-1294): 1298-1302
        • Tsien C.
        • Griffith K.A.
        • Sandler H.M.
        • et al.
        Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.
        Urology. 2003; 62: 93-98
        • Anscher M.S.
        • Robertson C.N.
        • Prosnitz R.
        Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update.
        Int J Radiat Oncol Biol Phys. 1995; 33: 37-43
        • Ku J.Y.
        • Lee C.H.
        • Ha H.K.
        Long-term oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer: systemic review and meta-analysis of 5-year and 10-year follow-up data.
        Korean J Urol. 2015; 56: 735-741
        • Freedland S.J.
        • Humphreys E.B.
        • Mangold L.A.
        • et al.
        Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
        JAMA. 2005; 294: 433-439
        • Taplin M.E.
        Biochemical (prostate-specific antigen) relapse: an oncologist's perspective.
        Rev Urol. 2003; 5: S3-S13
        • Stephenson A.J.
        • Eggener S.E.
        • Hernandez A.V.
        • et al.
        Do margins matter? The influence of positive surgical margins on prostate cancer-specific mortality.
        Eur Urol. 2014; 65: 675-680
        • D'Amico A.V.
        • Chen M.H.
        • Sun L.
        • et al.
        Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.
        BJU Int. 2010; 106: 1618-1622